Novo's Victoza approved for CV benefit

The expanded label could help boost the type 2 diabetes drug, which has seen competition eat away at its market share. 

By Jacob Bell • Aug. 28, 2017

Bristol-Myers, Pfizer continue to build case for Eliquis

The pharmas have been conducting follow-up study and real-world analyses of the anticoagulant in a bid to boost market uptake.

By Ned Pagliarulo • Aug. 28, 2017

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Adamas Parkinson's drug gains FDA approval

Gocovri is now the first drug OK'd for the treatment of dyskinesia in patients with the neurological disorder.

By Jacob Bell • Aug. 25, 2017

Novartis taps online retail exec for new digital role

New positions are needed for pharma companies seeking to speed technology adoption and incorporate digital into patient and clinical trial engagement.

By Lisa LaMotta • Aug. 24, 2017

In cost debate, Amgen stands by Repatha's value

New findings from an Amgen-backed study, while more supportive of the drug's value than other analyses, underscore the challenges posed by its hefty price tag.

By Ned Pagliarulo • Aug. 23, 2017

Alexion snags EU yes for new Soliris indication

The European Commission extended its approval of Soliris, allowing Alexion to sell the drug for another rare condition.

By Suzanne Elvidge • Aug. 23, 2017

ALK readies Odactra launch after Merck exit

The Danish drugmaker is ready to launch its house dust mite treatment after its big pharma partner pulled out of the collaboration in 2016.

By Lisa LaMotta • Aug. 22, 2017

PCSK9 inhibitors still too pricey, study finds

An analysis published in JAMA found list prices for the cholesterol-lowering drugs would need to be reduced to meet cost-effectiveness thresholds. 

By Ned Pagliarulo • Aug. 22, 2017

Cardiome shaken by FDA no-go on heart drug refiling

The Canadian drugmaker's stock fell by almost a quarter after disclosing the data package for Brinavess wasn't sufficient for a resubmitted New Drug Application.

By Jacob Bell • Aug. 22, 2017

Ironwood wins FDA approval for combo gout drug

The biotech expects the oral therapy to further grow its gout franchise, established last year with the acquisition of U.S. rights to Zurampic from AstraZeneca. 

By Ned Pagliarulo • Aug. 21, 2017

Insys settles opioid lawsuit for $4.5M

The deal with the Illinois Attorney General is one of several settlements the opiod drugmaker has reached with states over the marketing of its fentanyl-based painkiller Subsys.

By Suzanne Elvidge • Aug. 21, 2017

Expanded label boosts AstraZeneca and Merck's Lynparza

Securing a broader indication for earlier treatment of ovarian cancer should help Lynparza fend off competition from rival PARP inhibitors.

By Ned Pagliarulo • Aug. 18, 2017

House Democrats to probe 'skyrocketing' prices for MS meds

Two top Democrats on the House Oversight Committee plan to investigate the pricing strategies of seven leading drugmakers in the space.

By Ned Pagliarulo • Aug. 17, 2017

J&J deal gives Cerecor much-needed cash infusion

Stung by a clinical setback late last year, Cerecor sold off rights to a depression drug candidate to help fund its pipeline development. 

By Suzanne Elvidge • Aug. 16, 2017

Alexion bolsters Soliris patent defense

Three new patent grants, including one for composition of matter, should help keep competition to the rare disease drug at bay. 

By Jacob Bell • Aug. 16, 2017

South Carolina slaps Purdue with opioid lawsuit

As the U.S. grapples with an opioid overdose epidemic, the Palmetto State joins the recent legal scrutiny of painkiller drug manufacturers.

By Suzanne Elvidge • Aug. 16, 2017

Drug pricing — what you need to know

Controversy over rising drug prices has put industry on the defensive in recent years. In this Spotlight, BioPharma Dive explores the trends fueling the debate, as well as emerging responses. 

By Lisa LaMotta • Aug. 15, 2017

Could indication-based pricing really work?

Such a system rattles patients, but may be a model the industry can get behind.

By Malorye A. Branca • Aug. 14, 2017

5 Trends influencing drug pricing

When pricing medications, drugmakers now weigh consumer outrage, negotiating power and calls for transparency.

By Jacob Bell • Aug. 14, 2017

The secret recipe behind the launch price of a drug

Finding the right ingredients to set the perfect drug price is a little bit of art and a whole lot of science. 

By Lisa LaMotta • Aug. 14, 2017

Opioid drugmakers may have to slash production under new DEA proposal

The agency is mulling a 20% reduction in the manufacturing of the Schedule II drugs for 2018.

By Jacob Bell • Aug. 9, 2017

Payer coverage boosts Radius' Tymlos

A decision by Express Scripts to cover Tymlos preferentially in place of Eli Lilly's Forteo next year should give the biotech a leg up. 

By Ned Pagliarulo • Aug. 4, 2017

Dynavax dips as its hep B drug faces another setback

The FDA's request for more information on a planned, post-marketing study of Heplisav-B is pushing back an approval decision.

By Jacob Bell • Aug. 4, 2017

As Roche wades biosimilar waters, more competitors circle Herceptin

The FDA accepted two additional filings for versions of the breast cancer biologic earlier this week.

By Jacob Bell • Aug. 2, 2017

CVS Health removes 17 drugs from formulary, adds outcomes-based program

The pharmacy benefit manager put out its 2018 list, removing Eli Lilly's Jardiance while bringing back in Pfizer's Xtandi and J&J's Invokana.

By Lisa LaMotta • Aug. 2, 2017